EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evidence-Based Management of MASLD: GRADE Evaluation of Pharmacological Therapies

Eleni A Karavia iD, Andreas Pittaras iD, Ourania Andreopoulou iD, Aikaterini Hatziri, Amalia Makrydimitri, Dimitrios Anagnostopoulos, Patroklos Vareltzis iD, Kyriakos E Kypreos iD

Pharmaceuticals · 09.04.2026 · 19 (4) · 605

DOI: 10.3390/ph19040605 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 09.04.2026. Verfasst von Eleni A Karavia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology Laboratory, Department of Medicine, University of Patras, Rio Achaias, 26500 Patras, Greece. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hellenic Ministry of Education, Religious Affairs and Sports.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Non-alcoholic fatty liver disease (NAFLD), recently redefined as metabolic dysfunction-associated steatotic liver disease (MASLD), represents a growing global health burden closely linked to obesity, insulin resistance, and dietary patterns. Despite intense drug-development efforts, effective and widely approved pharmacological therapies remain limited.

Methods

In this work, we systematically evaluated the quality of clinical evidence supporting currently proposed pharmacological treatments for MASLD/MASLD using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework, focusing on phase III and IV clinical trials.

Results

Our analysis demonstrates that overall quality of evidence for most pharmacological agents ranges from very low to moderate, primarily due to imprecision and suspected publication bias.

Conclusions

Overall, our findings reinforce that, in the current therapeutic landscape, pharmacological therapies should be reserved for carefully selected patients and interpreted in the context of limited evidence certainty.

Schlagwörter

Stichwörter der Autor:innen

GRADE evaluationdevelopment and evaluationevidence-based managementgrading of recommendations assessmentmedicinesmetabolic dysfunction-associated liver diseasenon-alcoholic fatty liver disease

Autor:innen und Institutionen

  • Pharmacology Laboratory, Department of Medicine, University of Patras, Rio Achaias, 26500 Patras, Greece.
  • Adelco SA, 18346 Moschato, Greece.
  • Laboratory of Industrial Food Technologies and Agricultural Industries Technologies, Chemical Engineering Department, Faculty of Engineering, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.

ORCID-Profile: Eleni A Karavia, Andreas Pittaras, Ourania Andreopoulou, Patroklos Vareltzis, Kyriakos E Kypreos

Förderung

  • Hellenic Ministry of Education, Religious Affairs and Sports

Zitieren

APA

Karavia, E. A., Pittaras, A., Andreopoulou, O., Hatziri, A., Makrydimitri, A., Anagnostopoulos, D., Vareltzis, P., & Kypreos, K. E. (2026). Evidence-Based Management of MASLD: GRADE Evaluation of Pharmacological Therapies. Pharmaceuticals, 19(4), 605. https://doi.org/10.3390/ph19040605

Vancouver

Karavia EA, Pittaras A, Andreopoulou O, Hatziri A, Makrydimitri A, Anagnostopoulos D, et al. Evidence-Based Management of MASLD: GRADE Evaluation of Pharmacological Therapies. Pharmaceuticals. 2026;19(4):605. doi:10.3390/ph19040605

BibTeX
@article{Karavia2026,
  author = {Karavia, Eleni A and Pittaras, Andreas and Andreopoulou, Ourania and Hatziri, Aikaterini and Makrydimitri, Amalia and Anagnostopoulos, Dimitrios and Vareltzis, Patroklos and Kypreos, Kyriakos E},
  title = {Evidence-Based Management of MASLD: GRADE Evaluation of Pharmacological Therapies},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {4},
  pages = {605},
  doi = {10.3390/ph19040605}
}
Kostenlos starten →